

# Aaron B Waxman

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1339596/publications.pdf>

Version: 2024-02-01

149  
papers

7,289  
citations

50276

46  
h-index

60623

81  
g-index

156  
all docs

156  
docs citations

156  
times ranked

7675  
citing authors

#	ARTICLE	IF	CITATIONS
1	Interleukin-6 Overexpression Induces Pulmonary Hypertension. <i>Circulation Research</i> , 2009, 104, 236-244.	4.5	539
2	Circulating Mitochondrial DNA in Patients in the ICU as a Marker of Mortality: Derivation and Validation. <i>PLoS Medicine</i> , 2013, 10, e1001577.	8.4	354
3	Exercise-Induced Pulmonary Arterial Hypertension. <i>Circulation</i> , 2008, 118, 2183-2189.	1.6	318
4	Vascular stiffness mechanoactivates YAP/TAZ-dependent glutaminolysis to drive pulmonary hypertension. <i>Journal of Clinical Investigation</i> , 2016, 126, 3313-3335.	8.2	303
5	Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease. <i>New England Journal of Medicine</i> , 2021, 384, 325-334.	27.0	292
6	MicroRNA-21 Integrates Pathogenic Signaling to Control Pulmonary Hypertension. <i>Circulation</i> , 2012, 125, 1520-1532.	1.6	246
7	Sotatercept for the Treatment of Pulmonary Arterial Hypertension. <i>New England Journal of Medicine</i> , 2021, 384, 1204-1215.	27.0	224
8	Interleukin-6â€œInduced Protection in Hyperoxic Acute Lung Injury. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2000, 22, 535-542.	2.9	209
9	Matrix Remodeling Promotes Pulmonary Hypertension through Feedback Mechanoactivation of the YAP/TAZ-miR-130/301 Circuit. <i>Cell Reports</i> , 2015, 13, 1016-1032.	6.4	193
10	Persistent Exertional Intolerance After COVID-19. <i>Chest</i> , 2022, 161, 54-63.	0.8	186
11	Systems-level regulation of microRNA networks by miR-130/301 promotes pulmonary hypertension. <i>Journal of Clinical Investigation</i> , 2014, 124, 3514-3528.	8.2	182
12	Noninvasive Assessment of Murine Pulmonary Arterial Pressure. <i>Circulation: Cardiovascular Imaging</i> , 2010, 3, 157-163.	2.6	158
13	IL-13 stimulates vascular endothelial cell growth factor and protects against hyperoxic acute lung injury. <i>Journal of Clinical Investigation</i> , 2000, 106, 783-791.	8.2	150
14	Plasma gelsolin is a marker and therapeutic agent in animal sepsis*. <i>Critical Care Medicine</i> , 2007, 35, 849-855.	0.9	131
15	Genetic and hypoxic alterations of the micro <scp>RNA</scp> â€œ10â€œ<scp>ISCU</scp> 1/2 axis promote ironâ€œ sulfur deficiency and pulmonary hypertension. <i>EMBO Molecular Medicine</i> , 2015, 7, 695-713.	6.9	120
16	The Invasive Cardiopulmonary Exercise Test. <i>Circulation</i> , 2013, 127, 1157-1164.	1.6	116
17	Transcatheter Potts shunt creation in patients with severe pulmonary arterial hypertension: Initial clinical experience. <i>Journal of Heart and Lung Transplantation</i> , 2013, 32, 381-387.	0.6	114
18	PVDOMICS. <i>Circulation Research</i> , 2017, 121, 1136-1139.	4.5	113

#	ARTICLE	IF	CITATIONS
19	E/e <sup>2</sup> Ratio in Patients With Unexplained Dyspnea. <i>Circulation: Heart Failure</i> , 2015, 8, 749-756.	3.9	93
20	Effectiveness of Spironolactone Plus Ambrisentan for Treatment of Pulmonary Arterial Hypertension (from the [ARIES] Study 1 and 2 Trials). <i>American Journal of Cardiology</i> , 2013, 112, 720-725.	1.6	92
21	Plasma aldosterone levels are elevated in patients with pulmonary arterial hypertension in the absence of left ventricular heart failure: a pilot study. <i>European Journal of Heart Failure</i> , 2013, 15, 277-283.	7.1	91
22	NEDD9 targets COL3A1 to promote endothelial fibrosis and pulmonary arterial hypertension. <i>Science Translational Medicine</i> , 2018, 10, .	12.4	89
23	Bcl-2-related protein A1 is an endogenous and cytokine-stimulated mediator of cytoprotection in hyperoxic acute lung injury. <i>Journal of Clinical Investigation</i> , 2005, 115, 1039-1048.	8.2	85
24	Interleukin-11 and Interleukin-6 Protect Cultured Human Endothelial Cells from H <sub>2</sub> O <sub>2</sub> -Induced Cell Death. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2003, 29, 513-522.	2.9	82
25	IL-6 Protects against Hyperoxia-Induced Mitochondrial Damage via Bcl-2-Induced Bak Interactions with Mitofusions. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2009, 41, 385-396.	2.9	81
26	Measuring central pulmonary pressures during exercise in COPD: how to cope with respiratory effects. <i>European Respiratory Journal</i> , 2014, 43, 1316-1325.	6.7	80
27	The MicroRNA-130/301 Family Controls Vasoconstriction in Pulmonary Hypertension. <i>Journal of Biological Chemistry</i> , 2015, 290, 2069-2085.	3.4	80
28	The Inflammasome Mediates Hyperoxia-Induced Alveolar Cell Permeability. <i>Journal of Immunology</i> , 2010, 184, 5819-5826.	0.8	77
29	Right heart failure: Toward a common language. <i>Journal of Heart and Lung Transplantation</i> , 2014, 33, 123-126.	0.6	76
30	Impaired Systemic Oxygen Extraction at Maximum Exercise in Pulmonary Hypertension. <i>Medicine and Science in Sports and Exercise</i> , 2008, 40, 3-8.	0.4	75
31	Age-related upper limits of normal for maximum upright exercise pulmonary haemodynamics. <i>European Respiratory Journal</i> , 2016, 47, 1179-1188.	6.7	72
32	Protocol for Exercise Hemodynamic Assessment: Performing an Invasive Cardiopulmonary Exercise Test in Clinical Practice. <i>Pulmonary Circulation</i> , 2015, 5, 610-618.	1.7	68
33	Unexplained Exertional Dyspnea Caused by Low Ventricular Filling Pressures: Results from Clinical Invasive Cardiopulmonary Exercise Testing. <i>Pulmonary Circulation</i> , 2016, 6, 55-62.	1.7	67
34	Pulmonary Arterial Hypertension: New Insights Into the Optimal Role of Current and Emerging Prostacyclin Therapies. <i>American Journal of Cardiology</i> , 2013, 111, 1A-16A.	1.6	62
35	Accuracy of Echocardiography to Estimate Pulmonary Artery Pressures With Exercise. <i>Circulation: Cardiovascular Imaging</i> , 2017, 10, .	2.6	62
36	Inhaled treprostinil and forced vital capacity in patients with interstitial lung disease and associated pulmonary hypertension: a post-hoc analysis of the INCREASE study. <i>Lancet Respiratory Medicine</i> , 2021, 9, 1266-1274.	10.7	62

#	ARTICLE	IF	CITATIONS
37	A Simple Echocardiographic Method to Estimate Pulmonary Vascular Resistance. <i>American Journal of Cardiology</i> , 2013, 112, 873-882.	1.6	60
38	DNA Damage Induced by Hyperoxia. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2006, 35, 277-288.	2.9	58
39	Central Cardiac Limit to Aerobic Capacity in Patients With Exertional Pulmonary Venous Hypertension. <i>Circulation: Heart Failure</i> , 2015, 8, 278-285.	3.9	58
40	Invasive cardiopulmonary exercise testing in the evaluation of unexplained dyspnea: Insights from a multidisciplinary dyspnea center. <i>European Journal of Preventive Cardiology</i> , 2017, 24, 1190-1199.	1.8	58
41	Plasma Gelsolin Depletion and Circulating Actin in Sepsis—A Pilot Study. <i>PLoS ONE</i> , 2008, 3, e3712.	2.5	57
42	BOLA (Bola Family Member 3) Deficiency Controls Endothelial Metabolism and Glycine Homeostasis in Pulmonary Hypertension. <i>Circulation</i> , 2019, 139, 2238-2255.	1.6	54
43	IL-6 cytoprotection in hyperoxic acute lung injury occurs via PI3K/Akt-mediated Bax phosphorylation. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2009, 297, L6-L16.	2.9	52
44	Cytomegalovirus as a Primary Pulmonary Pathogen in AIDS. <i>Chest</i> , 1997, 111, 128-134.	0.8	51
45	Vasoreactivity to Inhaled Nitric Oxide with Oxygen Predicts Long-Term Survival in Pulmonary Arterial Hypertension. <i>Pulmonary Circulation</i> , 2011, 1, 250-258.	1.7	49
46	Multicenter implementation of a consensus-developed, evidence-based, spontaneous breathing trial protocol*. <i>Critical Care Medicine</i> , 2008, 36, 2753-2762.	0.9	48
47	Treprostinil Administered to Treat Pulmonary Arterial Hypertension Using a Fully Implantable Programmable Intravascular Delivery System. <i>Chest</i> , 2016, 150, 27-34.	0.8	48
48	Pulmonary Vascular Morphology as an Imaging Biomarker in Chronic Thromboembolic Pulmonary Hypertension. <i>Pulmonary Circulation</i> , 2016, 6, 70-81.	1.7	47
49	Targeted Lung Expression of Interleukin-11 Enhances Murine Tolerance of 100% Oxygen and Diminishes Hyperoxia-Induced DNA Fragmentation. <i>Chest</i> , 1999, 116, 8S-9S.	0.8	45
50	IL-6 Cytoprotection in Hyperoxic Acute Lung Injury Occurs via Suppressor of Cytokine Signaling-1-Induced Apoptosis Signal-Regulating Kinase-1 Degradation. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2009, 40, 314-324.	2.9	45
51	Anatomic Relationship of the Complex Tricuspid Valve, Right Ventricle, and Pulmonary Vasculature. <i>JAMA Cardiology</i> , 2019, 4, 478.	6.1	43
52	Conversion to Bosentan From Prostacyclin Infusion Therapy in Pulmonary Arterial Hypertension. <i>Chest</i> , 2006, 130, 1471-1480.	0.8	42
53	Network Analysis to Risk Stratify Patients With Exercise Intolerance. <i>Circulation Research</i> , 2018, 122, 864-876.	4.5	42
54	Exercise physiology and pulmonary arterial hypertension. <i>Progress in Cardiovascular Diseases</i> , 2012, 55, 172-179.	3.1	41

#	ARTICLE	IF	CITATIONS
55	Upregulation of the mammalian target of rapamycin complex 1 subunit Raptor by aldosterone induces abnormal pulmonary artery smooth muscle cell survival patterns to promote pulmonary arterial hypertension. <i>FASEB Journal</i> , 2016, 30, 2511-2527.	0.5	39
56	Functional impact of exercise pulmonary hypertension in patients with borderline resting pulmonary arterial pressure. <i>Pulmonary Circulation</i> , 2017, 7, 654-665.	1.7	38
57	Pulmonary Vascular Distensibility and Early Pulmonary Vascular Remodeling in Pulmonary Hypertension. <i>Chest</i> , 2019, 156, 724-732.	0.8	38
58	Dynamic right ventricular pulmonary arterial uncoupling during maximum incremental exercise in exercise pulmonary hypertension and pulmonary arterial hypertension. <i>Pulmonary Circulation</i> , 2019, 9, 1-10.	1.7	36
59	Left ventricular deformation at rest predicts exercise-induced elevation in pulmonary artery wedge pressure in patients with unexplained dyspnoea. <i>European Journal of Heart Failure</i> , 2017, 19, 101-110.	7.1	32
60	Right Ventricular-Arterial Uncoupling During Exercise in Heart Failure With Preserved Ejection Fraction. <i>Chest</i> , 2019, 156, 933-943.	0.8	32
61	Efficacy of Inhaled Treprostinil on Multiple Disease Progression Events in Patients with Pulmonary Hypertension due to Parenchymal Lung Disease in the INCREASE Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 205, 198-207.	5.6	32
62	Circulating endothelial and endothelial progenitor cells in patients with severe sepsis. <i>Microvascular Research</i> , 2011, 81, 216-221.	2.5	30
63	Right Heart Failure: Toward a Common Language. <i>Pulmonary Circulation</i> , 2013, 3, 963-967.	1.7	28
64	A four-tier classification system of pulmonary artery metrics on computed tomography for the diagnosis and prognosis of pulmonary hypertension. <i>Journal of Cardiovascular Computed Tomography</i> , 2018, 12, 60-66.	1.3	28
65	Unexplained exertional intolerance associated with impaired systemic oxygen extraction. <i>European Journal of Applied Physiology</i> , 2019, 119, 2375-2389.	2.5	28
66	Pulmonary haemodynamics during recovery from maximum incremental cycling exercise. <i>European Respiratory Journal</i> , 2016, 48, 158-167.	6.7	27
67	Exercise intolerance in pulmonary hypertension: mechanism, evaluation and clinical implications. <i>Expert Review of Respiratory Medicine</i> , 2016, 10, 979-990.	2.5	27
68	Comprehensive Diagnostic Evaluation of Cardiovascular Physiology in Patients With Pulmonary Vascular Disease. <i>Circulation: Heart Failure</i> , 2020, 13, e006363.	3.9	27
69	Anticoagulation in patients with pulmonary arterial hypertension: An update on current knowledge. <i>Journal of Heart and Lung Transplantation</i> , 2016, 35, 151-164.	0.6	23
70	Factors associated with adherence to phosphodiesterase type 5 inhibitors for the treatment of pulmonary arterial hypertension. <i>Journal of Medical Economics</i> , 2013, 16, 298-306.	2.1	22
71	Ranolazine Improves Right Ventricular Function in Patients With Precapillary Pulmonary Hypertension: Results From a Double-Blind, Randomized, Placebo-Controlled Trial. <i>Journal of Cardiac Failure</i> , 2021, 27, 253-257.	1.7	22
72	Pulmonary Vascular Resistance During Exercise Predicts Long-Term Outcomes in Heart Failure With Preserved Ejection Fraction. <i>Journal of Cardiac Failure</i> , 2018, 24, 169-176.	1.7	20

#	ARTICLE	IF	CITATIONS
73	Ultrasound-assisted catheter-directed thrombolysis compared with anticoagulation alone for treatment of intermediate-risk pulmonary embolism. <i>Pulmonary Circulation</i> , 2018, 8, 1-7.	1.7	20
74	Circulating NEDD9 is increased in pulmonary arterial hypertension: A multicenter, retrospective analysis. <i>Journal of Heart and Lung Transplantation</i> , 2020, 39, 289-299.	0.6	19
75	PULMONARY FUNCTION TEST ABNORMALITIES IN PULMONARY VASCULAR DISEASE AND CHRONIC HEART FAILURE. <i>Clinics in Chest Medicine</i> , 2001, 22, 751-758.	2.1	18
76	Open label study of ambrisentan in patients with exercise pulmonary hypertension. <i>Pulmonary Circulation</i> , 2017, 7, 531-538.	1.7	17
77	Totally Implantable IV Treprostinil Therapy in Pulmonary Hypertension Assessment of the Implantation Procedure. <i>Chest</i> , 2017, 152, 1128-1134.	0.8	16
78	Cicletanine for the Treatment of Pulmonary Arterial Hypertension. <i>Archives of Internal Medicine</i> , 2008, 168, 2164.	3.8	15
79	Inhaled Treprostinil in Pulmonary Hypertension Associated with Lung Disease. <i>Lung</i> , 2018, 196, 139-146.	3.3	15
80	Modulation of IGF-Binding Protein-2 and -3 in Hyperoxic Injury in Developing Rat Lung. <i>Pediatric Research</i> , 2005, 58, 222-228.	2.3	14
81	Conversion From Sildenafil to Tadalafil. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2014, 19, 550-557.	2.0	14
82	Dynamic right ventricular function response to incremental exercise in pulmonary hypertension. <i>Pulmonary Circulation</i> , 2020, 10, 1-8.	1.7	14
83	Sex-Related Differences in Dynamic Right Ventricular-Pulmonary Vascular Coupling in Heart Failure With Preserved Ejection Fraction. <i>Chest</i> , 2021, 159, 2402-2416.	0.8	13
84	Quantification of Arterial and Venous Morphologic Markers in Pulmonary Arterial Hypertension Using CT Imaging. <i>Chest</i> , 2021, 160, 2220-2231.	0.8	13
85	Recent advances in the management of pulmonary hypertension with interstitial lung disease. <i>European Respiratory Review</i> , 2022, 31, 210220.	7.1	13
86	Persistence and proliferation of human mesenchymal stromal cells in the right ventricular myocardium after intracoronary injection in a large animal model of pulmonary hypertension. <i>Cytotherapy</i> , 2017, 19, 668-679.	0.7	12
87	Rationale and design of the ranolazine PH-RV study: a multicentred randomised and placebo-controlled study of ranolazine to improve RV function in patients with non-group 2 pulmonary hypertension. <i>Open Heart</i> , 2018, 5, e000736.	2.3	12
88	Metabolomics of exercise pulmonary hypertension are intermediate between controls and patients with pulmonary arterial hypertension. <i>Pulmonary Circulation</i> , 2019, 9, 1-10.	1.7	12
89	Long-term results of the DelIVery for Pulmonary Arterial Hypertension trial. <i>Pulmonary Circulation</i> , 2019, 9, 204589401987861.	1.7	12
90	Association between lung ultrasound findings and invasive exercise haemodynamics in patients with undifferentiated dyspnoea. <i>ESC Heart Failure</i> , 2019, 6, 202-207.	3.1	12

#	ARTICLE	IF	CITATIONS
91	Safety and Efficacy of Transition from Inhaled Treprostinil to Parenteral Treprostinil in Selected Patients with Pulmonary Arterial Hypertension. <i>Pulmonary Circulation</i> , 2014, 4, 456-461.	1.7	11
92	Initial Data Report from "LARIAT" A Phase 2 Study of Bardoxolone Methyl in PAH Patients on Stable Background Therapy. <i>Chest</i> , 2015, 148, 639A.	0.8	11
93	The Dyspnea Clinic. <i>Circulation</i> , 2018, 137, 1994-1996.	1.6	11
94	A Novel Protective Role for Matrix Metalloproteinase-8 in the Pulmonary Vasculature. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 204, 1433-1451.	5.6	11
95	Pulmonary Arterial Hypertension: Evaluation and Management. <i>Southern Medical Journal</i> , 2007, 100, 393-399.	0.7	10
96	The role of IL-6 and IL-11 in hyperoxic injury in developing lung. <i>Pediatric Pulmonology</i> , 2008, 43, 297-304.	2.0	10
97	Pulmonary Hypertension in Heart Failure With Preserved Ejection Fraction. <i>Circulation</i> , 2011, 124, 133-135.	1.6	10
98	Using Clinical Trial End Points to Risk Stratify Patients With Pulmonary Arterial Hypertension. <i>Circulation</i> , 2015, 132, 2152-2161.	1.6	10
99	Neurovascular Dysregulation and Acute Exercise Intolerance in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. <i>Chest</i> , 2022, 162, 1116-1126.	0.8	10
100	Complications associated with the use of oral anticoagulation in patients with pulmonary arterial hypertension from two referral centers. <i>Pulmonary Circulation</i> , 2017, 7, 692-701.	1.7	9
101	The Tricuspid Valve Relationship With the Right Ventricle and Pulmonary Vasculature. <i>JACC: Cardiovascular Imaging</i> , 2019, 12, 564-565.	5.3	9
102	Pulmonary Vascular and Right Ventricular Burden During Exercise in Interstitial Lung Disease. <i>Chest</i> , 2020, 158, 350-358.	0.8	9
103	Loss of Pulmonary Vascular Volume as a Predictor of Right Ventricular Dysfunction and Mortality in Acute Pulmonary Embolism. <i>Circulation: Cardiovascular Imaging</i> , 2021, 14, e012347.	2.6	9
104	Hemodynamic and metabolic characteristics associated with development of a right ventricular outflow tract pressure gradient during upright exercise. <i>PLoS ONE</i> , 2017, 12, e0179053.	2.5	9
105	Case 14-2003. <i>New England Journal of Medicine</i> , 2003, 348, 1902-1912.	27.0	7
106	Roundtable debate: Controversies in the management of the septic patient--desperately seeking consensus. <i>Critical Care</i> , 2004, 9, E1.	5.8	7
107	Protocol for Vasoreactivity Testing With Epoprostenol in Pulmonary Hypertension. <i>Critical Pathways in Cardiology</i> , 2012, 11, 40-42.	0.5	7
108	Oral Prostacyclin Therapy for Pulmonary Arterial Hypertension. <i>Circulation</i> , 2013, 127, 563-565.	1.6	7

#	ARTICLE	IF	CITATIONS
109	Assessment of the quality of anticoagulation management in patients with pulmonary arterial hypertension. <i>Thrombosis Research</i> , 2017, 160, 83-90.	1.7	7
110	Impaired systemic oxygen extraction in treated exercise pulmonary hypertension: a new engine in an old car?. <i>Pulmonary Circulation</i> , 2018, 8, 1-4.	1.7	7
111	Right ventriculo-arterial uncoupling and impaired contractile reserve in obese patients with unexplained exercise intolerance. <i>European Journal of Applied Physiology</i> , 2018, 118, 1415-1426.	2.5	6
112	Fick principle and exercise pulmonary hemodynamic determinants of the six-minute walk distance in pulmonary hypertension. <i>Pulmonary Circulation</i> , 2020, 10, 1-9.	1.7	6
113	Systemic vascular distensibility relates to exercise capacity in connective tissue disease. <i>Rheumatology</i> , 2021, 60, 1429-1434.	1.9	6
114	A review of sitaxsentan sodium in patients with pulmonary arterial hypertension. <i>Vascular Health and Risk Management</i> , 2007, 3, 151-7.	2.3	6
115	Electromechanical Dissociation following Verapamil and Propranolol Ingestion: A Physiologic Profile. <i>Cardiology</i> , 1997, 88, 478-481.	1.4	5
116	Review: Portopulmonary hypertension: challenges in diagnosis and management. <i>Therapeutic Advances in Gastroenterology</i> , 2009, 2, 281-286.	3.2	5
117	Clinical trials in group 3 pulmonary hypertension. <i>Current Opinion in Pulmonary Medicine</i> , 2020, 26, 391-396.	2.6	5
118	Inspiratory flow patterns with dry powder inhalers of low and medium flow resistance in patients with pulmonary arterial hypertension. <i>Pulmonary Circulation</i> , 2021, 11, 1-10.	1.7	5
119	Phosphodiesterase-5 Inhibitors. <i>Handbook of Experimental Pharmacology</i> , 2013, 218, 229-255.	1.8	5
120	Towards Widespread Noninvasive Assessment of Pulmonary Vascular Resistance in Clinical Practice. <i>Journal of the American Society of Echocardiography</i> , 2014, 27, 108-109.	2.8	4
121	Pulmonary hypertension: work in progress. <i>Journal of Nuclear Cardiology</i> , 2003, 10, 413-423.	2.1	3
122	TREPROSTINIL SODIUM IMPROVES EXERCISE CAPACITY WHEN ADDED TO EXISTING ORAL PULMONARY ARTERIAL HYPERTENSION THERAPY. <i>Chest</i> , 2007, 132, 474B.	0.8	3
123	Development of a Right Ventricular Outflow Tract Gradient During Upright Exercise. <i>Journal of the American College of Cardiology</i> , 2017, 69, 595-597.	2.8	3
124	Arterial vascular volume changes with haemodynamics in schistosomiasis-associated pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2021, 57, 2003914.	6.7	3
125	Improving Decision Making for Massive Transfusions in a Resource Poor Setting: A Preliminary Study in Kenya. <i>PLoS ONE</i> , 2015, 10, e0127987.	2.5	3
126	Physiological Techniques and Pulmonary Hypertension - Left Heart Disease. <i>Progress in Cardiovascular Diseases</i> , 2016, 59, 30-41.	3.1	2



#	ARTICLE	IF	CITATIONS
127	Changes in Intraparenchymal Arterial and Venous Blood Distribution Quantified From CT Scans in Pulmonary Hypertension With Elevated Wedge Pressure. Chest, 2016, 150, 1179A.	0.8	1
128	Implantable system for treprostinil and lung transplantation: case series from delivery for pulmonary arterial hypertension study. Pulmonary Circulation, 2021, 11, 204589402199929.	1.7	1
129	Adherence to Phosphodiesterase Type 5 Inhibitors for the Treatment of Pulmonary Arterial Hypertension - A Real-World Analysis. Chest, 2011, 140, 736A.	0.8	1
130	Assessing Disease State in the Pulmonary Vasculature in Clinical Practice and Research. , 2016, , 219-229.		1
131	Cytomegalovirus as a Pulmonary Pathogen. Chest, 1997, 112, 861.	0.8	0
132	PREOPERATIVE INTRAVENOUS EPOPROSTENOL PRIOR TO SURGICAL REPAIR OF A VENTRICULAR SEPTAL DEFECT IN AN ADULT WITH EISENMENGER SYNDROME. Chest, 2006, 130, 305S.	0.8	0
133	MULTICENTER EXPERIENCE WITH THE RAPID TRANSITION TO INTRAVENOUS TREPROSTINIL FROM EPOPROSTENOL IN PULMONARY ARTERIAL HYPERTENSION. Chest, 2007, 132, 635A.	0.8	0
134	Response to Letter Regarding Article, "Exercise-Induced Pulmonary Arterial Hypertension" Circulation, 2009, 120, .	1.6	0
135	Quantification Of Number Of Circulating endothelial Cells In Patients With Severe Sepsis. , 2010, , .		0
136	Dysregulation Of Cell Cycle Proteins Is Associated With IL-6 Induced Pulmonary Vascular Remodeling And Pulmonary Arterial Hypertension. , 2011, , .		0
137	Extracellular Atp Triggers Hyperoxia-Induced Lung Inflammation. , 2011, , .		0
138	Changes in Intraparenchymal Arterial and Venous Blood Distribution Quantified From CT Scans in PAH. Chest, 2016, 150, 1175A.	0.8	0
139	Pulmonary Hypertension: An Integrative Approach to Assessment and Management. Clinics in Chest Medicine, 2021, 42, xiii-xiv.	2.1	0
140	A Woman with a Repaired Atrial Septal Defect and Pulmonary Hypertension with Worsening Dyspnea. Annals of the American Thoracic Society, 2021, 18, 1052-1058.	3.2	0
141	Group 1 Clinical Features and Treatment. , 2022, , 616-632.		0
142	LOW PLASMA GELSOLIN LEVEL IN SEPSIS IS ASSOCIATED WITH INCREASED MORTALITY.. Critical Care Medicine, 2005, 33, A163.	0.9	0
143	TREATMENT OF PORTOPULMONARY HYPERTENSION: EXPERIENCE WITH SILDENAFIL. Chest, 2006, 130, 256S.	0.8	0
144	IL-6 Inhibits Hyperoxia Induced Bax Translocation Through PI3kinase/AKT Mediated Bax Phosphorylation. FASEB Journal, 2008, 22, 1238.4.	0.5	0

#	ARTICLE	IF	CITATIONS
145	Inflammasome: A Pivotal Role in hyperoxia-induced acute lung injury?. FASEB Journal, 2009, 23, 1025.1.	0.5	0
146	Pulmonary Hypertension in Older Patients. , 2012, , 111-131.		0
147	Functional impact of exercise pulmonary hypertension in patients with borderline pulmonary arterial pressure. , 2017, , .		0
148	Prognostic impact of exercise pulmonary hypertension. , 2017, , .		0
149	The Failing Right Heart from Pulmonary Hypertension. Clinical Cases in Cardiology, 2020, , 147-169.	0.0	0